BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.341
+0.026 (8.12%)
At close: Dec 20, 2024, 4:00 PM
0.342
+0.001 (0.26%)
After-hours: Dec 20, 2024, 7:10 PM EST
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -89.17% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for BTAI stock have an average target of 5.00, with a low estimate of 1.00 and a high estimate of 7.00. The average target predicts an increase of 1,366.28% from the current stock price of 0.34.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 21, 2024.
Analyst Ratings
The average analyst rating for BTAI stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 5 | 5 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +1,366.28% | Oct 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +1,952.79% | Sep 6, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +1,952.79% | Aug 30, 2024 |
| UBS | UBS | Hold Maintains $3.5 → $1 | Hold | Maintains | $3.5 → $1 | +193.26% | Aug 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +1,952.79% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
3.66M
from 1.38M
Increased by 164.86%
Revenue Next Year
6.20M
from 3.66M
Increased by 69.74%
EPS This Year
-1.86
from -6.15
EPS Next Year
-1.59
from -1.86
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 5.6M | 9.3M | 26.3M | |||
| Avg | 3.7M | 6.2M | 20.1M | |||
| Low | 2.3M | 3.7M | 7.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 308.6% | 155.7% | 323.1% | |||
| Avg | 164.9% | 69.7% | 224.0% | |||
| Low | 63.3% | 2.2% | 20.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.60 | -1.09 | -0.80 | ||
| Avg | -1.86 | -1.59 | -1.13 | ||
| Low | -2.34 | -2.00 | -1.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.